Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2009

Boehringer Ingelheim Receives EC Clearance for Once-Daily Version of Parkinson's Therapy

  • The European Commission has sanctioned Boehringer Ingelheim’s prolonged-release, once-daily version of its Parkinson’s disease (PD) drug called Mirapexin®/Sifrol® (pramipexole). It is indicated for the treatment of early and advanced idiopathic PD.

    The approval was based on the submission of clinical trial results showing that the new formulation can offer an efficacy and safety profile comparable to the immediate-release tablet, which is taken three times daily.

    An NDA for the once-daily, extended-release formulation of pramipexole is under review with the FDA.

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »